Merck says FDA approves once-daily HIV combo pill Idvynso

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00
  • Merck won FDA clearance in April 2026 for once-daily HIV tablet IDVYNSO, a two-drug doravirine-islatravir regimen for virologically suppressed adults.
  • The drug is positioned as a switch option for patients on stable therapy with no prior virologic failure or known doravirine resistance.
  • Merck also struck an access agreement with the ADAP Crisis Task Force to support state AIDS Drug Assistance Programs serving more than 250,000 people.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260629823507) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.